Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | recruiting | Phase 2 | 22 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03961672 | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 15 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
| recruiting |
| Phase 2 |
| 40 |
| City of Hope Medical CenterOTHER |
| 1 |
| Jan 5, 2026 |
| clinicaltrials |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 114 | BeOne MedicinesINDUSTRY | 9 | Jan 2, 2026 | clinicaltrials |
| NCT04604067 | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | active not recruiting | Phase 2 | 260 | Swiss Cancer InstituteOTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT06736613 | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07062627 | Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma | recruiting | Phase 2 | 12 | Hyungwoo ChoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07189065 | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 150 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07283822 | Amping up With PemJAK | recruiting | Phase 2 | 53 | Seda S. ToluOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285590 | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma(IMCL-2023) | recruiting | Phase 2 | 50 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 2 | Dec 16, 2025 | clinicaltrials |
| NCT05410418 | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | active not recruiting | Phase 2 | 34 | Washington University School of MedicineOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07052695 | Mosunetuzumab for CLL MRD Clearance | recruiting | Phase 1 / Phase 2 | 40 | Inhye AhnOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03620903 | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | active not recruiting | Phase 2 | 53 | Christian BuskeOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05065554 | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | active not recruiting | Phase 2 | 12 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05168930 | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06986174 | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia | recruiting | Phase 2 | 30 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06390956 | Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) | recruiting | Phase 2 | 23 | University of UtahOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259122 | A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia(ZBR in WM) | not yet recruiting | Phase 2 | 43 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07254754 | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma(LATE-R-GEL-23) | recruiting | Phase 2 | 45 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT02570542 | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04484012 | Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06547866 | Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia(WAZABI) | not yet recruiting | Phase 2 | 102 | French Innovative Leukemia OrganisationOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07084662 | Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma | recruiting | Phase 2 / Phase 3 | 80 | Sun Yat-sen UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06958705 | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy | recruiting | Phase 2 | 79 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07247383 | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma | active not recruiting | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 120 | CRISPR Therapeutics AGINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT06550141 | Emapalumab Prevention of CAR-T Cell Associated Toxicities | recruiting | Phase 2 | 28 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06569680 | Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | Izidore Lossos, MDOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT06796998 | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | recruiting | Phase 2 | 25 | Izidore Lossos, MDOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | recruiting | Phase 2 | 227 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06544798 | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia | enrolling by invitation | Phase 2 | 276 | MeiraGTx, LLCINDUSTRY | 2 | Oct 16, 2025 | clinicaltrials |
| NCT06520098 | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(Benefit VA) | recruiting | Phase 2 | 100 | VA Office of Research and DevelopmentFED | 1 | Oct 14, 2025 | clinicaltrials |
| NCT07207785 | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma(FIL_PUMA) | not yet recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | recruiting | Phase 2 | 169 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07206264 | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment(ADAPT-MCL) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06925555 | Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04479267 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | active not recruiting | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | not yet recruiting | Phase 1 / Phase 2 | 12 | MingSight Pharmaceuticals, IncINDUSTRY | 0 | Sep 29, 2025 | clinicaltrials |
| NCT05192486 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 1 / Phase 2 | 12 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 62 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07144657 | Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma(GastricMALToma) | not yet recruiting | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07035379 | A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL | not yet recruiting | Phase 1 / Phase 2 | 66 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05788081 | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.(TOP-FLOR) | active not recruiting | Phase 2 | 40 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Aug 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 6, 2026source: clinicaltrials